Madhurima Singh, Executive Director at Alkem Laboratories, is spearheading a transformative period for the company, focusing on a dual strategy: fortifying its established pharmaceutical business while aggressively expanding into new healthcare ventures. Her leadership emphasizes building robust teams and capabilities to navigate a broader market landscape.
Expanding Alkem's Healthcare Footprint
Under Singh's direction, Alkem has made significant moves to diversify its portfolio. A key acquisition last year saw Alkem secure a majority stake in Switzerland-headquartered Occlutech, a specialist in minimally invasive cardiovascular devices. This strategic investment marks a crucial step into the medical technology sector.
Furthermore, Alkem's biotechnology division, Enzene, has broadened its global reach by establishing a contract development and manufacturing facility in the United States. The company has also created a dedicated subsidiary to bolster its trade generics business.
“The defining decision of the year was to widen Alkem’s field of play: to build new engines of growth beyond our established strengths, without loosening our grip on the core pharmaceutical business,” Singh stated.
Singh's approach to expansion is guided by stringent criteria. She insists that every new initiative must address three fundamental questions: “Do we have a genuine right to win? Can we build a capability that others cannot easily replicate? And will it still matter in 10 years?” This ensures that growth is not merely for expansion's sake but creates lasting value.
Sustaining Core Business and Financial Growth
Despite the focus on new ventures, the pharmaceutical business remains central to Alkem's strategy and continues to demonstrate strong performance. For the fiscal year 2026 (FY26), Alkem reported:
- Consolidated revenue of Rs14,712 crore, marking a 13.5% year-on-year increase.
- Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) rose 19.6% to Rs 3,005 crore.
- Profit after tax attributable to shareholders stood at approximately Rs 2,105 crore.
Revenue growth was balanced, with India operations growing 9.7% and international revenue increasing by a robust 22.5%.
Leadership in a Complex Environment
Managing multiple priorities has refined Singh's leadership philosophy, particularly in decision-making and team alignment. She acknowledges the challenge of complexity: “The biggest challenge was managing complexity without allowing it to slow us down.”
Her response involves fostering open discussion, clarifying priorities, and empowering teams to make decisions. Singh differentiates between reversible decisions, which can be made quickly, and those requiring more thorough scrutiny. She believes that effective execution hinges on seamless collaboration across the organization.
“A good strategy without alignment is a well-drawn map handed to people walking in different directions,” she remarked, underscoring her emphasis on unified effort.
Singh's leadership has evolved from providing direction to valuing listening, questioning assumptions, and enabling teams to find their own solutions, believing that true leadership helps others make better decisions.